|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Serum beta 2-microglobulin as a biomarker in inflammatory bowel disease显示文摘AIM: To investigate the diagnostic utility of beta 2 microglobulin(B2-M) levels and analyze this correlation with the activity of inflammatory bowel disease(IBD).METHODS: Overall, 78 IBD patients and 30 healthy controls were enrolled in the study. We examined B2-M serum levels in 43 ulcerative colitis(UC) patients, 35 with Crohn's disease(CD) and 30 control subjects, using an enzymatic method. Patients were divided into two groups according to two disease types: active and in remission. Subjects were also divided into two subgroups according to extent of the disease: left-side and pancolitis for UC and ileitis and ileocolitis for CD. All groups were compared for mean serum B2-M levels and also examined to see whether there was a correlation between serum B2-M levels and other inflammatory markers.RESULTS: The mean serum B2-M levels in the control group, UC and CD were 1.71, 2.41 and 2.24 respectively. B2-M values ≥ 1.96 mg/L had a 62% sensitivity, 76% specificity, a 79% positive predictive value, and a 58% negative predictive value for UC patients. B2-Mvalues ≥ 1.70 mg/L had 80% sensitivity, 53% specificity, 66% positive predictive value, and 69% negative predictive value for CD patients. Mean B2-M values were significantly higher in ulcerative colitis and Crohn's disease patients than in healthy controls(UC 2.41 ± 0.87 vs 1.71 ± 0.44, P = 0.002; CD 2.24 ± 1.01 vs 1.71 ± 0.44, P = 0.033). Also, mean B2-M values were significantly higher in active disease when compared to patients in remission(UC 2.66 ± 0.92 vs 1.88 ± 0.41, P = 0.004; CD 2.50 ± 1.15 vs 1.73 ± 0.31, P = 0.033). The difference between groups(UC and CD) in terms of serum B2-M levels was statistically insignificant(2.41 ± 0.87 vs 2.24 ± 1.01, P > 0.05 respectively).CONCLUSION: Serum B2-M levels may be used as an activity parameter in IBD. | Bülent Y|lmaz Seyfettin Kklü Osman Yüksel Serap Arslan | 2014 | World Journal of Gastroenterology2014，20，31： | 3 |
| 2 | Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors显示文摘AIM:To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors(PNETs)and provide consensus treatment recommendations.METHODS:Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs,angiogenesis inhibitors,inhibitors of mammalian target of rapamycinand cytotoxic agents.At this time,there is little data to guide treatment selection and sequence.We therefore assembled a panel of expert physicians to evaluate systemic treatment choices and provide consensus treatment recommendations.Treatment appropriateness ratings were collected using the RAND/UCLA modified Delphi process.After studying the literature,a multidisciplinary panel of 10 physicians assessed the appropriateness of various medical treatment scenarios on a 1-9 scale.Ratings were done both before and after an extended discussion of the evidence.Quantitative measurements of agreement were made and consensus statements developed from the second round ratings.RESULTS:Specialties represented were medical and surgical oncology,interventional radiology,and gastroenterology.Panelists had practiced for a mean of15.5 years(range:6-33).Among 202 rated scenarios,disagreement decreased from 13.2%(26 scenarios)before the face-to-face discussion of evidence to 1%(2)after.In the final ratings,46.5%(94 scenarios)were rated inappropriate,21.8%(44)were uncertain,and30.7%(62)were appropriate.Consensus statements from the scenarios included:(1)it is appropriate to use somatostatin analogs as first line therapy in patients with hormonally functional tumors and may be appropriate in patients who are asymptomatic;(2)it is appropriate to use everolimus,sunitinib,or cytotoxic chemotherapy therapy as first line therapy in patients with symptomatic or progressive tumors;and(3)beyond first line,these same agents can be used.In patients with uncontrolled secretory symptoms,octreotide LAR doses can be titrated up to 60 mg every4 wk or up to 40 mg every 3 or 4 wk.CONCLUSION:Using the Delphi process allowed physician experts to systematically obtain a consensus on the appropriateness of a variety of medical therapies in patients with PNETs. | Jonathan R Strosberg George A Fisher Al B Benson Lowell B Anthony Bulent Arslan John F Gibbs Edward Greeno Renuka V Iyer Michelle K Kim William J Maples Philip A Philip Edward M Wolin Dasha Cherepanov Michael S Broder | 2015 | World Journal of Gastroenterology2015，21，8： | 2 |
| 3 | Dexmedetomidine decreases emergence agitation in pediatric patients after sevoflurane anesthesia without surgery 显示文摘 | Isik B Arslan M Tunga A D | 2006 | Paediatr Anaesth2006，16，7： | 1 |
| 4 | Dexmedetomidine decreaesemergence agitation in pediatric patients after sevofluraneanesthesia without surgery 显示文摘 | Isik B Arslan M Tunga AD | 2006 | Pediatric Anesthesia2006，16，7： | 1 |
| 5 | Effects of intracerebroventricular injected choline on cardiovascular functions and sympathoadrenal activity 显示文摘 | Arslan B Y Ulus I H Savci I H | 1991 | J Cardiovase Pharmacol1991，17，5： | 1 |
| 6 | CT-guided transthoracic fine needle aspirationof pulmonary lesions: accuracy and complications in 294 patients显示文摘 | Arslan S Yilmaz A Bayramgurler B | 2002 | Sci Monit Med2002，8，7： | 1 |
| 7 | Outcome of non-metastatic male breast cancer: 118 patients 显示文摘 | Arslan UY Oksuzoglu B Ozdemir N | 2012 | Med On- col2012，29，2： | 1 |
| 8 | Interventional endoscopic ultrasound guided cholangiography:long-term experience of an emerging alternative to percutaneous transhepatic cholangiography显示文摘 | Maranki J Hernandez AJ Arslan B | | 0，，06： | 1 |
| 9 | Uretero-scopic pneumatic lithotripsy:is the location of the stone important in decision making? Analysis of 1296 patients显示文摘 | Gunlusoy B Degirmenci T Arslan M | 2008 | Endourol2008，22，2： | 1 |
| 10 | Larynx osteosarcoma: case report 显示文摘 | ARSLAN M ORHAN KIZILKAYA H YAL(2IN B | 2008 | J BUON2008，13，： | 1 |
| 11 | Comparison of hemo-dynamic effects of lidocaine,prilocaine and mepivacaine solu-tions without vasoconstrictor in hypertensive patients显示文摘 | Ezmek B Arslan A Delilbasi C | 2010 | J Appl Oral Sci2010，18，4： | 1 |
| 12 | A hybrid method for imputation of missing values using optimized fuzzy c-means with support vector regression and a genetic algorithm显示文摘 | Aydilek I B Arslan A | 2013 | Information Sciences2013，233，： | 1 |
| 13 | Effects of intracerebroventricular injected choline on cardiovascular functions and sympathoadrenal activity显示文摘 | Ulus I H Savci V | 1991 | J Cardiovasc Pharmacol1991，17，5： | 1 |
| 14 | Ureteroscopic pneumatic lithotripsy: is the location of the stone important in decision making? Analysis of 1296 patients 显示文摘 | Gunlusoy B Degirmenci T Arslan M | 2008 | J Endou- rol2008，22，2： | 1 |
| 15 | Dexraedetomidine decreases emergence agitation in pediatric patients after sevoflurane anesihesia without surgery显示文摘 | Isik B Arslan M Tunga AD | 2006 | Paediatr Anaesth2006，16，7： | 1 |
| 16 | Dexmedetomidine decreases emergence agitation in pediatric patients after sevoflurane anesthesia without surgery显示文摘 | ISIK B ARSLAN M TUNGA A D | 2006 | Paediatr Anaesth2006，16，7： | 1 |
| 17 | Unilateral optic neuropathy as the initial manifestation of euthyroid Graves' disease显示文摘 | ARSLAN E YAVA SO(LU I CILDA( B M | 2009 | Intern Med2009，48，22： | 1 |
| 18 | Bilateral single-session ureteroscopy with pneumatic lithotripsy for bilateral ureter stones feasible and safe显示文摘 | Gunlusoy B Deginnenci T Arslan M | 2008 | Urol Int2008，81，2： | 1 |
| 19 | Ureteroscopic pneumatic lithotripsy : is the location of the stone important in decision making? Analysis of 1296 patients 显示文摘 | Gunlusey B Degirmenci T Arslan M | 2008 | J Endourol2008，22，2： | 1 |
| 20 | CT-guided transthoracic fine needle aspiration of pulmonary lesions: accuracy and complicatiom in 294 patients显示文摘 | Arslan S Yilmaz A Bayr ungurler B | 2002 | Med Sci Monit2002，8，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员